<DOC>
	<DOCNO>NCT02207595</DOCNO>
	<brief_summary>The primary objective study investigate safety tolerability UCB5857 .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacokinetic Pharmacodynamic Profiles UCB5857 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>To eligible participate study , follow criterion must meet : An Independent Ethics Committee ( IEC ) approve write Informed Consent Form sign date subject Subject consider reliable capable adhere protocol ( eg , able understand complete diary ) , visit schedule , medication intake accord judgment Investigator Subject male female , 18 55 year age ( inclusive ) Female subject must negative pregnancy test urine Screening Visit negative serum pregnancy test Day 1 , nonchildbearing potential , define : 1 . Postmenopausal ( least 2 year Screening Visit ) , verify serum folliclestimulating hormone ( FSH ) level &gt; 40 mIU/mL Screening Visit , 2 . Permanently sterilize ( eg , tubal occlusion , hysterectomy , bilateral salpingectomy ) , 3 . Congenitally sterile Contraception method male subject female partner : 1 . Male subject partner childbearing potential must willing use condom sexually active 2 . The female partner childbearing potential male subject must willing use least 2 effective method contraception , include barrier method ( eg , male condom , female condom , diaphragm spermicide ) study period . Both sex must use mentioned contraception method ( condom male ) study 20 week last administration Investigational Medicinal Product ( IMP ) ( anticipated 5 halflives ) . Subject normal weight determine body mass index ( BMI ) 18.0 30.0 kg/m^2 ( inclusive ) , body weight least 50 kg Subject clinical laboratory test result within reference range test laboratory Subject Blood Pressure ( BP ) pulse within normal range supine position 5 minute rest ( systolic BP : 90 140 mmHg , diastolic BP : 50 90 mmHg , pulse : 40 90 beat per minute inclusive ) Subject 's ECG consider `` normal '' `` abnormal clinically nonsignificant '' ( interpreted Investigator ) Subjects permit enroll study follow criterion meet : Subject know hypersensitivity component Investigational Medicinal Product ( IMP ) Subject consider antihighaffinity immunoglobulin E ( IgE ) receptor nonresponsive CD63 induction basophil &lt; 10 % Subject cardiovascular cerebrovascular disease , include hypertension , angina , ischemic heart disease , transient ischemic attack , stroke , peripheral arterial disease sufficient cause symptom and/or require therapy maintain stable status Subject diabetes mellitus type require insulin Subject 1. active infection ( eg , sepsis , pneumonia , abscess ) 2. history latent , chronic , recurrent infection ( eg , tuberculosis [ TB ] , recurrent sinusitis , genital herpes , urinary tract infection ) risk infection ( surgery , trauma , infection require antibiotic , history skin abscess ) within 3 month IMP administration 3. experience significant episode gastroenteritis ( define loose stool associate abdominal pain and/or fever ) 7 day IMP administration When doubt , Investigator confer Sponsor 's Study Physician . Subject history positive TB test evidence possible TB latent TB infection Screening Visit ( QuantiFERONÂ® Gold Test ) Subject receive live attenuate vaccination within 3 month type vaccine within 4 week Screening Visit intend vaccination course study Subject follow hematology value Screening Visit : Hemoglobin ; woman &lt; 11 g/dL ; men &lt; 13 g/dL Absolute Neutrophil Count ( ANC ) &lt; 1.5 x 109/L ( &lt; 1000/mm^3 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>